Abstract:// Dennis Ruder 1, 2 , Vassiliki Papadimitrakopoulou 4 , Kazuhiko Shien 2 , Carmen Behrens 4 , Neda Kalhor 5 , Huiqin Chen 6 , Li Shen 3 , J. Jack Lee 6 , Waun Ki Hong 4 , Ximing Tang 2 , Luc Girard 7 , John D. Minna 7 , Lixia Diao 3 , Jing Wang 3 , Barbara Mino 2 , Pamela Villalobos 2 , Jaime Rodriguez-Canales 2 , Nana E. Hanson 2 , James Sun 9 , Vincent Miller 9 , Joel Greenbowe 9 , Garrett Frampton 9 , Roy S. Herbst 8 , Veera Baladandayuthapani 6 , Ignacio I. Wistuba 2 and Julie G. Izzo 2 1 Graduate Program in Human and Molecular Genetics and Cancer Biology, MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, Texas, USA 2 Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 3 Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 4 Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 5 Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 6 Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 7 Hamon Center for Therapeutic Oncology Research, The University of Texas Southwestern Medical Center, Dallas, Texas, USA 8 Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut, USA 9 Foundation Medicine, Inc., Cambridge, Massachusetts, USA Correspondence to: Julie G. Izzo, email: jizzo@mdanderson.org Ignacio I. Wistuba, email: iiwistuba@mdanderson.org Keywords: RICTOR gene abnormalities; KRAS mutation; MAPK pathway; mTORC2; non-small cell lung cancer Received: April 13, 2018 Accepted: September 09, 2018 Published: September 21, 2018 ABSTRACT Despite a therapeutic paradigm shift into targeted-driven medicinal approaches, resistance to therapy remains a hallmark of lung cancer, driven by biological and molecular diversity. Using genomic and expression data from advanced non-small cell lung cancer (NSCLC) patients enrolled in the BATTLE-2 clinical trial, we identified RICTOR alterations in a subset of lung adenocarcinomas and found RICTOR expression to carry worse overall survival. RICTOR-altered cohort was significantly enriched in KRAS/MAPK axis mutations, suggesting a co-oncogenic driver role in these molecular settings. Using NSCLC cell lines, we showed that, distinctly in KRAS mutant backgrounds, RICTOR blockade impairs malignant properties and generates a compensatory enhanced activation of the MAPK pathway, exposing a unique therapeutic vulnerability. In vitro and in vivo concomitant pharmacologic inhibition of mTORC1/2 and MEK1/2 resulted in synergistic responses of anti-tumor effects. Our study provides evidence of a distinctive therapeutic opportunity in a subset of NSCLC carrying concomitant RICTOR/KRAS alterations.

Supplemental Figures and Table from Mtor and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors

Mtor and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors.

Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of -altered non-small cell lung cancer.

Mtorc1-Driven Tumor Cells Are Highly Sensitive to Therapeutic Targeting by Antagonists of Oxidative Stress

Compensatory combination of mTOR and TrxR inhibitors to cause oxidative stress and regression of tumors

Synthetic Lethality of Combined Glutaminase and Hsp90 Inhibition in Mtorc1-Driven Tumor Cells

Supplementary Figures S1-S9 from Activation of PP2A and Inhibition of Mtor Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma

Figure S2 Inhibition of Mtorc1 and Glutamate Cysteine Ligase Induces Cytotoxicity in Tsc2-/- MEFs from Mtorc1-Driven Tumor Cells Are Highly Sensitive to Therapeutic Targeting by Antagonists of Oxidative Stress

Table S2 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the Mtorc1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma

Supplementary Data 1 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma

Dual Targeting of AKT and Mammalian Target of Rapamycin: a Potential Therapeutic Approach for Malignant Peripheral Nerve Sheath Tumor.

Supplementary Figure S6 from Targeted Therapy of &Lt;i>tert</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy

EXTH-63. MTA-COOPERATIVE PRMT5 INHIBITORS ARE EFFICACIOUS IN MTAP-DELETED MALIGNANT PERIPHERAL NERVE SHEATH TUMOR MODELS

Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer

Abstract 4568: Rational targeting of BCL-xL and/or mTOR enhance the efficacy of KRASG12D inhibitor in pancreatic cancer

Activation of mammalian target of rapamycin pathway confers adverse outcome in nonsmall cell lung carcinoma.

A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.

Supplementary Figures 1 - 11, Tables 1 - 2 from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from Mtor Inhibitor Therapy

Antiangiogenic Therapy Using Sunitinib Combined with Rapamycin Retards Tumor Growth but Promotes Metastasis.

Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK

Genomic And Molecular Characterization Of Malignant Peripheral Nerve Sheath Tumor Identifies The Igf1r Pathway As A Primary Target For Treatment (Publication With Expression Of Concern. See Vol. 25, Pg. 3195, 2019)